Ligand Pharmaceuticals (Nasdaq: LGND) will hold its annual Investor and Analyst Day on Tuesday, December 10 in Boston. The in-person event will include presentations from Ligand’s senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook.
A live webcast of the event will also be accessible on this page upon registration.
Ligand seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Its business model focuses on funding mid- to late-stage drug programs for economic rights, acquiring royalty interests, and licensing technologies. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner.
A live question and answer session will follow the formal presentation.
